# OnCo record shine (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/shine/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "shine", "NCT01776840" ;
  schema:name "SHINE"@en ;
  schema:alternateName "Ibrutinib with bendamustine and rituximab in untreated mantle cell lymphoma"@en, "SHINE trial"@en ;
  schema:description "Adding a targeted tablet to first-line chemotherapy gave older people with mantle cell lymphoma about two and a half more years before the disease returned, but they did not live longer."@en ;
  schema:url <https://onco.cc/trials/shine/> ;
  schema:dateModified "2026-10-01"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01776840>, <https://doi.org/10.1056/NEJMoa2201817> ;
  onco:status "mixed" ;
  onco:tag "lymphoma-evidence" ;
  onco:phase "3" ;
  schema:startDate "2013-05-16" ;
  onco:cancers <https://onco.cc/cancers/mantle-cell-lymphoma/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/>, <https://onco.cc/fronts/chemotherapy/> ;
  onco:targets <https://onco.cc/targets/btk/>, <https://onco.cc/targets/cd20/>, <https://onco.cc/targets/ccnd1/> ;
  onco:drugs <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/drugs/rituximab/> ;
  onco:companies <https://onco.cc/companies/johnson-johnson/> ;
  onco:pathways <https://onco.cc/pathways/bcr-signalling/> ;
  onco:terms <https://onco.cc/terms/maintenance-therapy/>, <https://onco.cc/terms/lymphoma-tx-maintenance/> ;
  onco:trials <https://onco.cc/trials/triangle/>, <https://onco.cc/trials/enrich/> ;
  onco:people <https://onco.cc/people/michael-wang/>, <https://onco.cc/people/martin-dreyling/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-toxicity-qol/>, <https://onco.cc/bottlenecks/b-aging-comorbidity/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-shine-ibrutinib-bendamustine-rituximab-mantle-cell-nejm-2022/> .